North American peptide therapeutics market is estimated to project a CAGR of 5.1%, during the forecast period. The high per capita healthcare expenditure coupled with the increasing investment in modern healthcare technologies are the key factors that are anticipated to drive the growth of the peptide therapeutics market in the region. Pfizer Inc., Merck & Co. Inc., Eli Lilly, and Co., and GlaxoSmithKline Plc among others are some of the global key players of the peptide therapeutics market operating in the region.

Visit for Global Peptide Therapeutics Market Report at: https://www.omrglobal.com/industry-reports/peptide-therapeutics-market

The North American peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into parenteral administration and oral administration. On the basis of application, the market is segmented into cancer, metabolic disorder (diabetes & obesity), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others including chronic kidney diseases, osteoporosis, and autoimmune disorder. Among these applications, metabolic disorder dominates the market in North America. The increasing prevalence of diabetes created the demand for insulin and hence drives market growth.

Geographically, the North American peptide therapeutics market is segmented into the US and Canada. The US accounted for a major share in the market in 2019 due to the presence of key peptide therapeutics manufacturers and the high number of patients living with diabetes in the region coupled with the high consumption of insulin in the country. The Canadian peptide therapeutics market tends to grow at the fastest CAGR of around 6.4% during the forecast period. The major factors attributing to the fastest growth of Canada in the market include the country’s high R&D funding in healthcare, increasing per-capita healthcare expenditure, and technological advancements in the healthcare sector.

Furthermore, some of the key players in the market include Eli Lilly & Co., Amgen Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Co., and others. These companies are using several strategies to expand market share and gain a competitive advantage over their competitors. The strategies include new product launches, mergers and acquisitions, partnerships, and collaborations. For instance, in August 2020, Amgen Inc. declared the US FDA expansion of the KYPROLIS (carfilzomib) to include its use in combination with DARZALEX (daratumumab) plus dexamethasone (DKd) in two dosing regimens, once weekly and twice weekly, to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have received one to three previous lines of therapy.

Research Methodology

The market study of the North American peptide therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Authentic public databases 
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for drug manufacturing companies, pharmaceutical companies, insulin manufacturers, diabetes management companies, government organizations, regulatory bodies, hospitals & pharmacies, research institutes, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models. 

Market Segmentation:

1. North American Peptide Therapeutics Market Research and Analysis by Route of Administration
2. North American Peptide Therapeutics Market Research and Analysis by Application

The Report Covers:

• Comprehensive research methodology of the North American peptide therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the North American peptide therapeutics market.
• Insights about market determinants which are stimulating the North American peptide therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.